The Top 5 Biosimilars Articles for the Week of October 23

The Center for Biosimilars® recaps the top 5 stories in biosimilars news for the week of October 23.


Hi, I’m Kelly Davio for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of October 23.

Number 5: Novartis credits stronger-than-expected sales of its biosimilars for strong third-quarter net income.

Number 4: Etanercept has been shown to significantly reduce overall healthcare utilization for patients with rheumatoid arthritis, especially for patients who are highly compliant with therapy.

Number 3: New evidence suggests that anti—tumor necrosis factor agents could be repurposed to treat depression that is unresponsive to existing therapies.

Number 2: The FDA has released new educational materials on biosimilars. The resources, geared toward clinicians, include webinars, staff presentations, graphics, and sharable social media assets.

Number 1: The RAND corporation has released a new report on biosimilars, estimating that the United States could save $54 billion over the next 10 years by using biosimilars.

To read all of these articles and more, visit